Substituted indolines which inhibit receptor tyrosine kinases

US6762180B1 · kind B1 · utility

Assignee

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Gerald Juergen Roth · Biberach, DE
• Armin Heckel · Biberach an der Riß, DE
• Rainer Walter · Biberach, DE
• Jacobus Van Meel · Biberach, DE
• Norbert Redemann · Biberach, DE
• Ulrike Tontsch-Grunt · Baden, AT
• Walter Spevak · Stockerau, AT
• Frank Hilberg · Wien, AT

Key dates

• Filing date: Oct 3, 2000
• Grant date: Jul 13, 2004
• Expiry date: Dec 10, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are:(a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone,(b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and(c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.